Megan S. Lim MD PhD, and Kojo S. J. Elenitoba-Johnson MD, University of Michigan, Ann Arbor, MI
Adam Bagg, MD, University of Pennsylvania, Philadelphia, PA
The application of new technologies for the diagnosis and prognostication of hematopoietic disorders has contributed to the current practice of hematopathology. Recent and emerging advances in next-generation sequencing technologies and genomic medicine will result in a paradigmatic change in the practice of hematopathology.
The course will provide a background on the principles and concepts of molecular hematopathology and personalized medicine. An overview of commonly used molecular tests as well as an update of new technologies including array comparative genomic hybridization and next-generation sequencing using targeted and whole genome/exome sequencing will be provided. Approaches to myeloid neoplasms and lymphomas in the era of personalized medicine will be discussed using case-based studies.
This course is designed for trainees and practicing pathologists with an interest in hematopathology and genomic medicine who seek to update and expand their knowledge base regarding emerging technologies that will impact the discipline of hematopathology.
Upon completion of this educational activity, participants should be able to: 1) Identify concepts of personalized medicine in the context of hematopathology; 2) Understand the appropriate diagnostic and prognostic value of specific molecular tests in the evaluation of hematopoietic neoplasms; and 3) Appreciate how novel genetic alterations in myeloid and lymphoid neoplasms impact patient management. Registrants will receive a detailed text syllabus including references at the meeting, and the PowerPoint presented at the Annual Meeting will be made available after the meeting on the USCAP website.